olmesartan has been researched along with Liver Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelsalam, RM; Abo El-Nasr, NME; El-Abhar, HS; Mahmoud, SS; Nofal, SM; Safar, MM; Saleh, DO | 1 |
1 other study(ies) available for olmesartan and Liver Dysfunction
| Article | Year |
|---|---|
Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Liver; Liver Diseases; Male; Rats, Wistar; Receptor for Advanced Glycation End Products; Renin-Angiotensin System; Signal Transduction; STAT3 Transcription Factor; Tetrazoles | 2020 |